Last reviewed · How we verify
Corticosteroid with lidocaine
Corticosteroid with lidocaine, developed by Vanderbilt University Medical Center, is a marketed drug with a key composition patent expiring in 2028. The drug's key strength lies in its combination of anti-inflammatory and anesthetic properties, which may offer enhanced patient comfort and efficacy. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Corticosteroid with lidocaine |
|---|---|
| Sponsor | Vanderbilt University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OMT for Adhesive Capsulitis (PHASE4)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Microneedling for Burn Hypertrophic Scars (NA)
- Knee Injections for Obese Patients With Knee Arthritis (PHASE4)
- A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder (PHASE4)
- The Effect of Local Corticosteroid Injection in Carpal Tunnel Syndrome Patients With Type 2 Diabetes
- Pericapsular Nerve Group Block Added to Intra-articular Corticosteroid Injection in the Treatment of Hip Pain
- Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroid with lidocaine CI brief — competitive landscape report
- Corticosteroid with lidocaine updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI